Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPSE | Q9Y251 | 2/20 | 0.48 |
| ▸ | MGAM | O43451 | 11/20 | 0.46 |
| ▸ | GAA | P10253 | 11/20 | 0.46 |
| ▸ | SI | P14410 | 11/20 | 0.46 |
| ▸ | MGAM2 | Q2M2H8 | 11/20 | 0.46 |
| ▸ | APLNR | P35414 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5650808 | 0.91 | MGAM (0.48) | HPSEMGAMGAASIMGAM2 | |
| SCHEMBL5651271 | 0.89 | MGAM (0.50) | HPSEMGAMGAASIMGAM2 | |
| SCHEMBL5650016 | 0.87 | MGAM (0.48) | HPSEMGAMGAASIMGAM2 | |
| SCHEMBL5652928 | 0.84 | HPSE (0.53) | HPSEMGAMGAASIMGAM2 | |
| SCHEMBL5651334 | 0.84 | HPSE (0.57) | HPSEMGAMGAASIMGAM2 | |
| SCHEMBL5653967 | 0.83 | AURKA (0.45) | HPSEKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL5647407 | 0.81 | CNR1 (0.41) | HPSECNR2 | |
| SCHEMBL5649151 | 0.80 | HDAC6 (0.45) | KDM4EALDH1A1HPGDHSD17B10HTT | |
| SCHEMBL5652259 | 0.78 | PRSS12 (0.47) | HPGDCNR2 | |
| SCHEMBL5653824 | 0.78 | AURKA (0.45) | HPSEKDM4EALDH1A1HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7220769-B2 | Azolylbenzamides and analogues and their use for treating osteoporosis | NIKEM RESEARCH S.R.L. (IT) | 2007-05-22 | — | — | US | disclosed |
| US-20050038095-A1 | Azolylbenzamides and analogues and their use for treating osteoporosis | 3-V BIOSCIENCES, INC. | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038095-A1 | Azolylbenzamides and analogues and their use for treating osteoporosis | NR0B2, NR0B1, NCOR1 | HPSE 3728/4885MGAM 3224/4885GAA 4139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.